NCT00364988

Pioglitazone and Losartan Provides Additional Renoprotection

Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 32 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.

Conditions

• Type 2 Diabetes
• Diabetic Nephropathy

Interventions

Type	Name	Description
DRUG	pioglitazone+losartan	Pioglitazone (30 mg/daily) losartan (100 mg daily)
DRUG	losartan	losartan (100 mg daily)

Timeline

• Start date: 2005-01-01
• Primary completion: 2005-12-01
• Completion: 2006-01-01
• First posted: 2006-08-16
• Last updated: 2014-10-27